Fibrosis Model - NASH / MASH

Developing effective therapies for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) presents major challenges—lack of reliable preclinical models, difficulty in replicating disease progression, and identifying translatable biomarkers for clinical trials. With no FDA-approved treatments, sponsors need robust, predictive preclinical models to evaluate therapeutic candidates efficiently.

At MLM Medical Labs, we understand these challenges and provide validated, nutrient-deficient MASH models designed to:

Replicate disease progression seen in humans
Provide translatable biomarkers to bridge preclinical and clinical research
Deliver high-quality, reproducible data to de-risk drug development

How We Solve MASH Preclinical Challenges:

Challenge: Current MASH models often fail to capture the complex metabolic and inflammatory environment of the disease.
Our Solution: We offer nutrient-deficient diet models that accurately reflect MASH pathology, improving the predictability of therapeutic responses.

Challenge: Sponsors need clear, translatable endpoints to move confidently into clinical trials.
Our Solution: Our comprehensive readouts—including liver enzyme assessment, histopathology, and body weight tracking—provide actionable insights to support regulatory submissions.

Validated Nutrient-Deficient MASH (formerly NASH) Models:

• Methionine and Choline Deficient Diet (MCD) – induces rapid liver injury and fibrosis
• Choline Deficient, High-Fat Diet (CHDFD) – mimics obesity-associated MASH

Key Readout Options:

• Body weight measurements – track disease progression
• Liver enzyme assessments – evaluate hepatotoxicity and therapeutic impact
• Liver histopathology analysis – assess fibrosis, inflammation, and steatosis

With MLM Medical Labs as your partner, you gain a trusted preclinical solution that reduces study variability, enhances data reliability, and accelerates drug development—bringing your MASH therapy one step closer to clinical success